Wanbury Limited, a pharmaceutical company headquartered in Navi Mumbai, Maharashtra, India, has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending June 30, 2025. The certificate, issued by its Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., confirms the dematerialization of shares and compliance with depository norms.
Wanbury Limited, a pharmaceutical company based in Navi Mumbai, Maharashtra, India, has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This update pertains to the quarter ended 30 June 2025, reinforcing the company’s adherence to regulatory frameworks.
The certificate was issued by Purva Sharegistry (India) Pvt. Ltd., Wanbury’s Registrar and Share Transfer Agent (RTA), registered with SEBI under registration number INR000001112. In the letter dated 01 July 2025, the RTA confirmed that all security certificates received from depository participants for dematerialization during the said quarter were either accepted or rejected and duly processed. The securities were verified, mutilated, and canceled, and the names of the depositories were substituted in the register of members as the registered owners, all within prescribed timelines.
Wanbury Limited, listed on both BSE (Scrip Code: 524212) and NSE (Symbol: WANBURY), stated that the dematerialized securities have been updated with the respective stock exchanges. The confirmation letter lists shareholders and entities such as Kingsbury Investments Inc., Classic Share & Stock Broking, and individual investors who completed dematerialization during the quarter.
This submission strengthens Wanbury’s commitment to transparent governance and timely compliance with SEBI’s regulatory framework.
For more information, visit BSE.
